FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283206908> ?p ?o ?g. }

• W4283206908 abstract "Abstract Background Endometrial cancer (EC) is a common gynecologic malignancy and patients with advanced and recurrent EC have a poor prognosis. Although chemotherapy is administered for those patients, the efficacy of current chemotherapy is limited. Therefore, it is necessary to develop novel therapeutic agents for EC. In this study, we focused on lipolysis-stimulated lipoprotein receptor (LSR), a membrane protein highly expressed in EC cells, and developed a chimeric chicken–mouse anti-LSR monoclonal antibody (mAb). This study investigated the antitumor effect of an anti-LSR mAb and the function of LSR in EC. Methods We examined the expression of LSR in 228 patients with EC using immunohistochemistry and divided them into two groups: high-LSR ( n = 153) and low-LSR groups ( n = 75). We developed a novel anti-LSR mAb and assessed its antitumor activity in an EC cell xenograft mouse model. Pathway enrichment analysis was performed using protein expression data of EC samples. LSR-knockdown EC cell lines (HEC1 and HEC116) were generated by transfected with small interfering RNA and used for assays in vitro. Results High expression of LSR was associated with poor overall survival (hazard ratio: 3.53, 95% confidence interval: 1.35–9.24, p = 0.01), advanced stage disease ( p = 0.045), deep myometrial invasion ( p = 0.045), and distant metastasis ( p < 0.01). In EC with deep myometrial invasion, matrix metalloproteinase (MMP) 2 was highly expressed along with LSR. Anti-LSR mAb significantly inhibited the tumor growth in EC cell xenograft mouse model (tumor volume, 407.1 mm 3 versus 726.3 mm 3 , p = 0.019). Pathway enrichment analysis identified the mitogen-activated protein kinase (MAPK) pathway as a signaling pathway associated with LSR expression. Anti-LSR mAb suppressed the activity of MAPK in vivo. In vitro assays using EC cell lines demonstrated that LSR regulated cell proliferation, invasion, and migration through MAPK signaling, particularly MEK/ERK signaling and membrane-type 1 MMP (MT1-MMP) and MMP2. Moreover, ERK1/2-knockdown suppressed cell proliferation, invasion, migration, and the expression of MT1-MMP and MMP2. Conclusions Our results suggest that LSR contributes to tumor growth, invasion, metastasis, and poor prognosis of EC through MAPK signaling. Anti-LSR mAb is a potential therapeutic agent for EC." @default.
• W4283206908 created "2022-06-22" @default.
• W4283206908 creator A5002700571 @default.
• W4283206908 creator A5004882510 @default.
• W4283206908 creator A5009314886 @default.
• W4283206908 creator A5018600874 @default.
• W4283206908 creator A5020771892 @default.
• W4283206908 creator A5024504740 @default.
• W4283206908 creator A5030259502 @default.
• W4283206908 creator A5032604446 @default.
• W4283206908 creator A5055405608 @default.
• W4283206908 creator A5058902589 @default.
• W4283206908 creator A5071731375 @default.
• W4283206908 creator A5074483951 @default.
• W4283206908 creator A5078716608 @default.
• W4283206908 creator A5086167183 @default.
• W4283206908 creator A5087796447 @default.
• W4283206908 date "2022-06-21" @default.
• W4283206908 modified "2023-09-25" @default.
• W4283206908 title "Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer" @default.
• W4283206908 cites W1886431664 @default.
• W4283206908 cites W1967421306 @default.
• W4283206908 cites W1969605298 @default.
• W4283206908 cites W1979337120 @default.
• W4283206908 cites W1979390430 @default.
• W4283206908 cites W1988439811 @default.
• W4283206908 cites W1999068456 @default.
• W4283206908 cites W1999966467 @default.
• W4283206908 cites W2005613383 @default.
• W4283206908 cites W2007287727 @default.
• W4283206908 cites W2023805676 @default.
• W4283206908 cites W2031222466 @default.
• W4283206908 cites W2047630282 @default.
• W4283206908 cites W2059664914 @default.
• W4283206908 cites W2066113694 @default.
• W4283206908 cites W2081145901 @default.
• W4283206908 cites W2081236313 @default.
• W4283206908 cites W2091022821 @default.
• W4283206908 cites W2094112385 @default.
• W4283206908 cites W2107336169 @default.
• W4283206908 cites W2113017183 @default.
• W4283206908 cites W2115991409 @default.
• W4283206908 cites W2120965358 @default.
• W4283206908 cites W2135947389 @default.
• W4283206908 cites W2140864364 @default.
• W4283206908 cites W2144679405 @default.
• W4283206908 cites W2154204112 @default.
• W4283206908 cites W2154536753 @default.
• W4283206908 cites W2157016650 @default.
• W4283206908 cites W2158371473 @default.
• W4283206908 cites W2159482845 @default.
• W4283206908 cites W2170352900 @default.
• W4283206908 cites W2170661611 @default.
• W4283206908 cites W2273988729 @default.
• W4283206908 cites W2323292054 @default.
• W4283206908 cites W2464755258 @default.
• W4283206908 cites W2560287982 @default.
• W4283206908 cites W2756523589 @default.
• W4283206908 cites W2768729693 @default.
• W4283206908 cites W2883866157 @default.
• W4283206908 cites W2889446290 @default.
• W4283206908 cites W2914238967 @default.
• W4283206908 cites W2944434395 @default.
• W4283206908 cites W3006211741 @default.
• W4283206908 cites W3025735868 @default.
• W4283206908 cites W3043135743 @default.
• W4283206908 cites W3114765718 @default.
• W4283206908 cites W4210989197 @default.
• W4283206908 cites W4243413044 @default.
• W4283206908 cites W4294216483 @default.
• W4283206908 doi "https://doi.org/10.1186/s12885-022-09789-6" @default.
• W4283206908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35729527" @default.
• W4283206908 hasPublicationYear "2022" @default.
• W4283206908 type Work @default.
• W4283206908 citedByCount "1" @default.
• W4283206908 countsByYear W42832069082022 @default.
• W4283206908 crossrefType "journal-article" @default.
• W4283206908 hasAuthorship W4283206908A5002700571 @default.
• W4283206908 hasAuthorship W4283206908A5004882510 @default.
• W4283206908 hasAuthorship W4283206908A5009314886 @default.
• W4283206908 hasAuthorship W4283206908A5018600874 @default.
• W4283206908 hasAuthorship W4283206908A5020771892 @default.
• W4283206908 hasAuthorship W4283206908A5024504740 @default.
• W4283206908 hasAuthorship W4283206908A5030259502 @default.
• W4283206908 hasAuthorship W4283206908A5032604446 @default.
• W4283206908 hasAuthorship W4283206908A5055405608 @default.
• W4283206908 hasAuthorship W4283206908A5058902589 @default.
• W4283206908 hasAuthorship W4283206908A5071731375 @default.
• W4283206908 hasAuthorship W4283206908A5074483951 @default.
• W4283206908 hasAuthorship W4283206908A5078716608 @default.
• W4283206908 hasAuthorship W4283206908A5086167183 @default.
• W4283206908 hasAuthorship W4283206908A5087796447 @default.
• W4283206908 hasBestOaLocation W42832069081 @default.
• W4283206908 hasConcept C121608353 @default.
• W4283206908 hasConcept C126322002 @default.
• W4283206908 hasConcept C159654299 @default.
• W4283206908 hasConcept C173396325 @default.
• W4283206908 hasConcept C203014093 @default.
• W4283206908 hasConcept C204232928 @default.
• W4283206908 hasConcept C2779013556 @default.

• next